Company: WHWK
Filing Date: 2025-01-31
Form Type: DEFM14A
Source: 0001193125-25-018470
Chunk: 107

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-01-31
Form: DEFM14A
Chunk 107
---
-GAAPfinancial measures, which would otherwise require a reconciliation of a non-GAAPfinancial measure to a GAAP financial measure. Reconciliations of non-GAAPfinancial measures were not relied upon by Leerink Partners for purposes of its financial analysis as described above in the section titled “ —Opinion of Aadi Financial Advisor” or by Aadi’s board of directors in connection with their consideration of the Divestiture. Non Risk-Adjusted FYARRO Projections Set forth below is a summary of the non risk-adjusted FYARRO projections, which are select projected financial information for the FYARRO business for fiscal years 2025 through 2039 (the year in which Aadi management assumed patent protections for FYARRO will expire) based on information as prepared by Aadi management in connection with Aadi’s evaluation of the Divestiture. The non risk-adjusted FYARRO projections were not probability-adjusted and included, among other things, the following key assumptions regarding the FYARRO business and 2025-2039 costs of goods sold (“COGS”), 2025-2039 research and development (“R&D”) expense, and 2025-2039 selling, general and administrative (“SG&A”) expense, in each case as to which there can be no assurance:

| • |     | revenue projections for the FYARRO business in the United States for 2025 and 2026 based on bottom-up demand analysis, with an assumed 3% annual growth rate thereafter from 2027-2039; |

| • |     | no additional indications beyond PEComa or associated development spend; |

| • |     | FYARRO is commercialized by a partner in the European Union in 2027 and a 20% royalty is paid on net sales in the 
 territory;                                                                                                        |

| • |     | $3.0 million and $4.0 million of COGS in 2025 and 2026, respectively; |

| • |     | COGS equal to 11.5% of U.S. revenue from 2026-2039, incorporating a 7.5% royalty payable to BMS under the 
 existing license agreement with BMS;                                                                      |

| • |     | for R&D expense, an aggregate of $166.0 million in unadjusted CMC and quality assurance expenses for 
 2025-2039;                                                                                           |

| • |     | for R&D expense, $11.0 million and $